The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq ...

Shares of Lupin rose nearly 4 percent after the pharmaceutical major announced the launch of Mirabegron Extended-Release tablets (25 mg) in the United States, a drug which has over $1 billion in ...

Use Robitussin Cough + Chest Congestion DM Maximum Strength (Oral) exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than ...

AHMEDABAD, India, April 22, 2024--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") announces the ...

The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq ...

The Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement. The company's product is a generic ...

Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 25 mg in US markets. Mirabegron extended-release tablets, 25 mg ...

Dave Sanders for The New York Times Supported by By Troy Closson It sounds like a dream for some working parents: school for 12 hours a day, starting bright and early at 7 a.m. and ending after ...

The company has launched Mirabegron extended-release tablets in strength of 25 mg in the US market after having ... had annual sales of USD 2.42 billion in the US. Zydus shares were trading 2.9 per ...